Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become
clinically available in some countries, which has greatly increased the need for biomarker …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Importance Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread
implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient …

Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …

Executive summary The number of older people, including those living with dementia, is
rising, as younger age mortality declines. However, the age-specific incidence of dementia …